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Resolving the genetic heterogeneity of prelingual
hearing loss within one family: Performance
comparison and application of two targeted next
generation sequencing approaches
Yu Lu1,8, Xueya Zhou2,3,8, Zhanguo Jin4,8, Jing Cheng1, Weidong Shen1, Fei Ji1, Liyang Liu2, Xuegong Zhang2,
Michael Zhang2,5, Ye Cao6,7, Dongyi Han1, KwongWai Choy6,7 and Huijun Yuan1
Here, we report an unconventional Chinese pedigree consisting of three branches all segregating prelingual hearing loss (HL)
with unclear inheritance pattern. After identifying the cause of one branch as maternally inherited aminoglycoside-induced HL,
targeted next generation sequencing (NGS) was applied to identify the genetic causes for the other two branches. One affected
subject from each branch was subject to targeted NGS whose genomic DNA was enriched either by whole-exome capture
(Agilent SureSelect All Exon 50Mb) or by candidate genes capture (Agilent SureSelect custom kit). By NGS analysis, we
identiﬁed that patients from Branch A were compound heterozygous for p.E1006K and p.D1663V in the CDH23 (DFNB12)
gene; and patients from Branch B were homozygous for IVS7-2A4G in the SLC26A4 (DFNB4) gene. Both CDH23 mutations
altered conserved calcium binding sites of the extracellular cadherin domains. The co-occurrence of three different genetic
causes in this family was exceedingly rare but fully compatible with the mutation spectrum of HL. Our study has also raised
several technical and analytical issues when applying the NGS technique to genetic testing.
Journal of Human Genetics (2014) 59, 599–607; doi:10.1038/jhg.2014.78; published online 18 September 2014
INTRODUCTION
Hearing loss (HL) is the most common sensorineural disorder.
Severe–to-profound HL affects one of every 1000 neonates. The
prevalence increases to about 0.2% before the age of 5 years when
languages have been acquired.1,2 It has been estimated that about two-
thirds of these cases have a genetic origin, most of which are
monogenic.2 Prelingual HL is typically inherited as an autosomal
recessive trait with or without accompanying other syndromic
features.3 To date, over 160 loci have been identiﬁed for hereditary
HL, including more than 90 for autosomal recessive nonsyndromic
HL (NSHL) and more than 60 for autosomal dominant NSHL. At
least 44 genes for autosomal recessive NSHL and 27 genes for
autosomal dominant NSHL have been identiﬁed (http://hereditary-
hearingloss.org, accessed in October 2013). These genes encode
proteins participating in a variety of functions: gap junctions, ion
homeostasis, extracellular (EC) matrix, transcription factors, cell
adhesion, motor proteins, etc. attesting the complexity of hearing
mechanism and the genetic heterogeneity of HL.4
Discovering the causal mutations is crucially important for HL
diagnosis, especially for prelingual cases. It allows direct estimates of
recurrence risk in relatives and helps family planning. In some
circumstances, establishing an early genetic diagnosis can also predict
the possible phenotypic outcomes and suggest personalized preventa-
tive and therapeutic options. As an example, Usher syndromes, which
are characterized by both HL and gradual visual impairment, share the
same disease genes as several types of autosomal recessive NSHL but
are not readily distinguished from autosomal recessive NSHL in
infants and early childhood.5 For newborns diagnosed with Usher
syndromes, effective measures can slow down or even prevent the
progression into retinitis pigmentosa if implemented in time.6
The extremely high genetic heterogeneity of HL makes genetic
testing particularly challenging. The target enrichment (TGE) of exons
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for speciﬁc or all genes related to a disease followed by next generation
sequencing (NGS) allows a comprehensive survey of mutations
affecting protein-coding genes. A number of recent studies reported
the application of NGS targeting either the exons of known HL genes
(e.g., references 7–11) or the whole exome (e.g., Woo et al.12) in
molecular diagnosis of HL. Notwithstanding their positive ﬁndings,
some technical issues like the enrichment performance although
thoroughly evaluated for some commercial exome kits13,14 remain
under-explored for most custom TGE kits. Analytical issues on
distinguishing pathogenic mutations from low frequency polymorph-
isms also persist and confound the clinical interpretations.
In this study, we report an unconventional Chinese family JX-H016
presenting prelingual HL with unknown inheritance pattern. After
identifying the cause of one branch as maternally inherited
aminoglycoside-induced HL, targeted NGS was applied to identify
the genetic causes for the other two branches. Their genomic DNAs
were enriched by a commercial whole-exome kit and a custom
designed HL kit (CUHK-HL V1) targeting 252 known and candidate
HL genes, respectively. The NGS analysis quickly led to the identiﬁca-
tion of disease-causing mutations in the SLC26A4 and the CDH23
genes for the two other branches. The signiﬁcance and implications of
the ﬁndings from this family was discussed in light of the mutation
spectrum of HL. We also compared the performances of two TGE kits
and discussed the issues to be considered when designing a custom
TGE kit.
MATERIALS AND METHODS
Clinical evaluation
A four-generation Chinese non-consanguineous family, JX-H016, was recruited
from an isolated village located in the Jiangxi province in mainland China
(Figure 1a). Twenty-two family members including 9 affected subjects and 13
individuals with normal hearing participated in this study. This study was
approved by the Ethnic Committee of Chinese PLA General Hospital. Written
informed consent was obtained from the adult participants and the guardians
on behalf of the children prior to their participation in the study. A medical
history was collected using a standard questionnaire, including the age at onset,
severity and progression of HL, medication, family history, visual impairment,
and other relevant clinical manifestations. All participants underwent audio-
logical examinations including pure-tone audiometry at frequencies
250–8000 Hz, which were found to be consistent with bone conduction values.
Immittance testing was applied to evaluate middle-ear pressure, ear canal
volumes and tympanic membrane mobility. The degree of HL was evaluated
based on the average of audiometric thresholds at 500, 1000 and 2000Hz.
Designing the custom TGE kit
We designed a custom TGE kit (CUHK-HL V1) for the molecular diagnosis of
hereditary HL. The kit was designed to target a total of 252 human protein-
coding genes related to HL. It included 78 known HL genes (55 nonsyndromic
Figure 1 The pedigree and typical audiograms of patients. (a) The four-generation pedigree of the Chinese family presenting prelingual HL is comprised of
three branches (labeled A~C). The affected individuals could only be found in the third generation. Individuals with available DNAs in the second and the
third generation were genotyped for the four pathogenic mutations. Two affected members (III-4 and III-13) from the third generation were selected for
sequencing. (b) Typical audiograms of selected patients from each branch are shown. While patients in Branch A and B showed bilateral severe-to-profound
hearing loss across all frequencies, patients in Branch C all showed severe hearing losses with down-sloping shaped audiograms (only III-29 is shown).
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and 23 syndromic HL genes) and 174 candidate HL genes collected based on
the functional evidence in knockout mice or from literature survey. The list of
78 known HL genes is given in Supplementary Table S1. We adopted Agilent
(Santa Clara, CA, USA) SureSelect TGE technology to manufacture the assay
chemistries. As compared with the commercial SureSelect 50Mb whole-exome
kit, it differs in several aspects of the design (summarized in Table 1 and
illustrated in Figure 2a). The target regions of the commercial SureSelect All
Exon 50Mb (SureSelect 50Mb) kit contain all protein-coding exons annotated
by the GENCODE project15 as well as 10 bp ﬂanking sequences. In addition,
they also include exons of small non-coding RNAs from miRBase and Rfam. In
comparison, the CUHK-HL V1 kit was designed to capture only 252 protein-
coding genes. All exons including untranslated regions and their 50 base pair
(bp) ﬂanking sequences were selected for capture. In addition, the CUHK-HL
V1 kit also included the full length mitochondrial DNA (mtDNA) as a single
target. We deﬁned the exonic region for a gene as the coding exons plus 10 bp
intron–exon boundaries and found that more exonic regions of HL genes are
covered by the CUHK-HL V1 kit than SureSelect 50Mb. About 99.2% of the
exonic regions of 55 human NSHL genes are covered by the designed targets of
the CUHK-HL V1 kit but only 94.2% by the SureSelect 50Mb kit. A notable
example is the PTPRQ gene, which is virtually not included in the targets of the
SureSelect 50Mb kit (Supplementary Table S2). Both kits use 120 bp
biotinylated cRNA oligonucleotide baits complementary to the target DNA
sequences to hybridize the NGS libraries, but they differ in the bait layouts at
targeted regions. While the SureSelect 50Mb kit contains baits that reside
immediately adjacent to each other across the target intervals, the CUHK-HL
V1 kit contains densely overlapping baits that cover each target base four times
on average (fourfold tiling).
Targeted NGS
We used the SureSelect 50Mb and the CUHK-HL V1 kits to capture the
genomic DNA of one affected member in Branch A (III-4) and one affected
member from Branch B (III-13), respectively (Figure 1a). The experimental
procedures were similar for the two kits. Genomic DNA was extracted and
puriﬁed from peripheral blood leucocytes using QIAamp DNA blood kit
(Qiagen, Duesseldorf, Germany). The qualiﬁed 3 μg genomic DNA for each
sample was randomly sheared into 150~ 250 bp fragments (Covaris, Woburn,
MA, USA) and puriﬁed using MinElute PCR puriﬁcation kit (Qiagen). The
fragments were end-repaired, adenylated and ligated to adapters at both ends
using NEBNext DNA sample preparation kit (New England Biolabs, Ipswich,
MA, USA). The adapter-ligated templates were puriﬁed by the Agencourt
AMPure SPRI XP beads (Beckman Coulter, Brea, CA, USA); and the fragments
with insert size about 250 bp were excised. Extracted DNA was PCR ampliﬁed,
puriﬁed and hybridized to the SureSelect biotinylated RNA library for target
capture (Agilent). A total of 500 ng puriﬁed ampliﬁed library was hybridized to
the custom-designed biotinylated cRNA probes for 24 h at 65 °C. Hybridized
fragments were enriched using streptavidin-coated magnetic Dynabeads
(Invitrogen, Carlsbad, CA, USA), whereas non-hybridized fragments were
washed out after 24 h. Captured PCR products were subjected to Agilent 2100
Bioanalyzer to evaluate the magnitude of enrichment. The library enriched
by the CUHK-HL V1 kit was sequenced on Illumina HiSeq 2000 (Illumina,
San Diego, CA, USA) in 90 bp paired-end (PE) reads. The library enriched by
the SureSelect 50Mb kit was sequenced on GAIIx in 100 bp PE reads using
three lanes. Raw image ﬁles were processed by Illumina CASAVA Software
version 1.7 for base-calling with default parameters.
To validate and test the segregation pattern of the prioritized variants,
primers were designed to amplify the encompassing genomic region. PCR
products were sequenced in both forward and reverse directions on an ABI
3100 using the BigDye Terminator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems, Carlsbad, CA, USA).
Bioinformatics analysis
Raw sequence reads were aligned to the reference genome (NCBI Build 37)
using Burrows-Wheeler Aligner (BWA, v0.5.9). The sequence alignment ﬁles
were processed by Picard (v1.55, http://picard.sourceforge.net) to mark up
duplicated reads and calculate summary statistics. Genome Analysis Tool Kit
(GATK, v.1.4–9) was used to perform realignment around indels and base
quality recalibration to produce analysis-ready alignments. Single-nucleotide
variants (SNVs) and small insertion deletions (indels) were called using GATK’s
Uniﬁed Genotyper module. High-quality variants were obtained by GATK’s
recommended ﬁltering parameters under single sample calling mode.
The depth of coverage on given target regions was calculated using the
DepthOfCoverage module of GATK. Only high-quality bases (Q4= 20) on
non-duplicated reads with high mapping quality (MAPQ4= 17) were
included in evaluating the depth of coverage.
To prioritize the disease-causing variants, we excluded the variants whose
allele frequencies are greater than 0.01 in both the public databases and the
in-house exome database consisting 170 unrelated samples. The threshold of
0.01 was chosen based on the currently known most common HL-causing
mutations in China.16 The functional effects were then annotated by
ANNOVAR based on the refSeq Gene model. The evolutionary conservation
for at each variant position was measured by Genome Evolutionary Rare
Proﬁling (GERP) and PhyloP. We then focused on the functionally inter-
pretable variants that included: SNVs that were evolutionarily conserved
(GERP42.0) and caused missense or nonsense changes; or SNVs that were
located within 2 bp of intron–exon boundaries; and indels that caused in-frame
or frameshift alternations. To aid the interpretation of missense SNVs, their
pathogenic effect predictions were queried from dbNSFP.17
RESULTS
Pedigree description
The pedigree of family JX-H016, which spanned four generations and
comprised 53 members, consisted of three branches (A~C) all
segregating prelingual HL. Affected subjects with hearing impairment
were only found in the third generation (Figure 1a). The inheritance
pattern of this family was unclear. However, when we checked each
branch, it was consistent with the autosomal recessive mode. The
patients from Branch A and B showed prelingual severe–to-profound
HL at all frequencies, whereas the patients from Branch C showed
prelingual severe HL with down-sloping audiograms (Figure 1b and
Table 1 Comparing the design differences between the CUHK-HL V1 and the SureSelect 50Mb target enriched kits
Target enrichment kit CUHK-HL V1 SureSelect 50Mb
Target region length (bp) 2 062 107 51 646 629
Number of baits 52 049 556 569
Baits layout Overlapping baits, fourfold tiling across the target
intervals
Intermediately adjacent, head-to-tail anchored baits across the
target intervals
Targeted gene groups 78 known HL genes+174 candidates+entire
mtDNA
GENCODE coding genes+noncoding RNAs from miRBase and
Rfam
Targeted regions for each gene All exons and UTRs+50 bp ﬂanking sequences All coding exons+10 bp ﬂanking sequences
Proportion of the NSHL gene regionsa covered by the
designed targets
0.992 0.942
Abbreviations: bp, base pair; UTR, un-translated regions.
aGene regions are deﬁned as all coding exons plus 10 bp ﬂanking sequences at intron–exon junctions.
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Figure 2 Comparing the design and performance of the two target enrichment (TGE) kits. (a) The targeted regions, bait layouts, GC percent and depth of
coverage at the GJB2 gene locus. The CUHK-HL V1 kit was targeting at both coding sequences and untranslated regions using fourfold tiling baits, whereas
the commercial SureSelect 50Mb kit was designed to capture only the protein-coding part of the gene using baits that were adjacently riveted to each other.
The inﬂuence of local GC percent on the read depth is more evident with the CUHK-HL V1 kit: the exon 1 of GJB2 co-localizes with a CpG island on which
no reads were mapped; across the exon2, the read depth tended to decrease with increasing GC percent. (b) Enrichment efﬁciency and the mtDNA effect.
Enrichment efﬁciency can be measured by the proportion of total mapped bases that overlap the designed target regions (on-target proportion). Although the
CUHK-HL V1 kit showed a higher on-target proportion than the SureSelect 50Mb kit (~75% vs ~60%), nearly two-thirds of on-target bases were mapped
onto mtDNA which is designed as a single target. (c) Comparing the uniformity of read depths across all NSHL genes. To account for the differences in the
designed targets of two TGE kits, the comparison is restricted to the genomic intervals that encompass all coding exons plus 10bp intron–exon boundaries of
the NSHL genes (exonic intervals) that overlap the target regions in both TGE kits. To account for the differences in the total sequence amounts, the depth
per interval is then normalized by dividing the average depth over the exonic intervals under comparison. The cumulative distributions of the normalized
depth on the exonic intervals are shown. The curve can be interpreted as the achieved coverage proportions (y axis) at different normalized depths (x axis).
For the normalized depth ranging from 0 to 0.5, we found the SureSelect 50Mb kit consistently but slightly outperformed the CUHK-HL V1 kit on the
coverage proportions. (d) The effect of GC content on read depths. Similar to (c), we compared the two TGE kits by using normalized depth over all targeted
exonic regions of the NSHL genes. The pattern is quantitatively similar when using all targets. For both kits, regions with very high GC contents (40.7) had
very low depths. While the SureSelect 50Mb kit shows a parabolic relationship between read depth and GC content, the depths on the CUHK-V1 kit targets
decrease monotonically with GC content. The difference can most likely be explained by the differences in the bait design. (e) The effect of repeat elements
on coverage depths. Because the SureSelect TGE technology tends to avoid placing baits over repeat elements, target regions with low bait density should
have higher densities of repeat elements. For the CUHK-HL V1 kit, under the fourfold tiling of 120 bp baits, the expected density should be 1/30; low bait
density was deﬁned as o1/50 based on the empirical bait density distribution. After accounting for the GC effect, read depths at the targets of low bait
density tend to be shallower than targets with normal bait density. The inﬂuence of the bait density on target depth can also be observed for the SureSelect
50Mb kit (see Table 6).
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Table 2). The severity of hearing impairment did not progress with
increasing patient age. Tinnitus and vertigo were not reported by this
family. Audiologic evaluation demonstrates normal immittance testing
and sensorineural hearing impairment. On the basis of the ques-
tionnaires, three affected subjects from Branch C, III-20, III-24 and
III-29, had historical exposures to gentamicin or streptomycin (dose
uncertain) at the age of 0–2 years. Comprehensive family medical
histories and clinical examination of these individuals showed no other
clinical abnormalities, including diabetes, cardiovascular diseases,
visual problems and neurological disorders. The detailed clinical data
of affected subjects of family JX-H016 were summarized in Table 2.
Identiﬁcation of mitochondrial 12S rRNA A1555G mutation in
family JX-H016
Because of the aminoglycoside exposures of some patients in this
family, we ﬁrstly conducted the Sanger sequence to detect the
mitochondrial 12S rRNA A1555G mutation in all patients of this
family. The homoplasmic A1555G mutation was carried by II-6 and
all her offsprings, and presumably also carried by the female offsprings
in the fourth generation of Branch C. The 12S rRNA A1555G
mutation was not carried by any patient from the other two branches.
Other mutations in mitochondrial 12S rRNA were also excluded.
Identiﬁcation of CDH23 and SCL26A4mutations in family JX-H016
by NGS with two TGE kits
After excluding the mutations in mitochondrial 12S rRNA and GJB2
gene by Sanger sequence, we elected to use the targeted NGS to resolve
the genetic causes of Branch A and B. Affected subject III-4 from
Branch A and III-13 from Branch B were selected for sequencing. The
genomic library of III-4 was enriched by the SureSelect 50Mb kit; and
19.58 giga base pairs raw sequences were generated using 100 bp PE
reads. BWA mapped 95.8% of those reads to the reference genome;
and 30.7% of them were marked as duplicates. Not accounting for the
duplicated reads and reads with low mapping quality (MAPQo17),
the mean read depth on targets is 131.2 × . The genomic library of
III-13 was enriched by the CUHK-HL V1 kit; and a total of 836Mb
raw sequences were generated using 90 bp PE reads. BWA mapped
98.7% of the reads to the genome, of which 15.8% were marked as
duplicates. The mean target depth achieved for III-13 is 213.6× . More
than 38 000 and 1700 high-quality variants were called for III-4 and
III-13, respectively. After a series of ﬁltering, both patients carried four
rare mutations disrupting known NSHL genes (Table 3 and
Supplementary Figure S1). In affected subject III-13, we identiﬁed
the homozygous splicing mutation c.919-2A4G, also known as
IVS7-2A4G, of the SLC26A4 (DFNB4) gene. The mutation abolished
the splice acceptor of exon 8 and was predicted to skip the entire
Table 2 Summary of clinical data of affected individuals of family JX-H016
Patient Gender Age (years) Use of
aminoglycoside
Hearing test PTAa (dB) Audiogram shape Tinnitus Vertigo Noise exposure
At testing At onset Left ear Right ear
III-1 Female — Prelingual — — — — — — —
III-2 Female 36 Prelingual No — — — — — —
III-4 Female 35 Prelingual No 97 100 Flat No No No
III-10 Male — Prelingual — — — — — — —
III-11 Female 35 Prelingual No 100 90 Sloping No No No
III-13 Female 27 Prelingual No 98 98 Flat No No No
III-15 Female 24 Prelingual No 100 100 Flat No No No
III-17 Male 29 Prelingual No 88 90 Flat No No No
III-20 Female — Prelingual Yes — — — — — —
III-22 Female — Prelingual Yes — — — — — —
III-24 Female 28 Prelingual Yes 82 83 Sloping No No No
III-29 Male 17 Prelingual Yes 77 82 Sloping No No No
aPTA, pure-tone average.
Table 3 The number of high-quality variants after each step of ﬁltering
III-13 III-4
SNVs Indels SNV Indels
All high-quality variants 1492 220 35728 2416
After ﬁltering against public databasesa 50 131 1172 1129
After in-house ﬁltering against in-house exome databaseb 36 22 719 58
After functional effects ﬁlteringc 11 1 196 14
Variants disrupting known nonsyndromic hearing loss genes 4 0 4 0
Genes harboring homozygous variants or 4=2 heterozygous variants 1 2
Recessive hearing loss genes harboring homozygous variants or 4=2 heterozygotes 1 1
Abbreviations: indels, insertions-deletions; SNV, single-nucleotide variants.
aExcluding variants having alternative allele frequencies 40.01 in any one of the populations in dbSNP and 1000 genomes.
bExcluding variants having alternative allele frequencies 40.01 in 170 other unrelated in-house exomes.
cKeeping SNVs that are evolutionarily conserved and cause missense, nonsense changes or potentially disrupt splice sites; and keeping indels that result in inframe or frameshift alternations.
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exon 818 resulting in a truncated protein product. Sanger sequencing
conﬁrmed the co-segregation of the homozygote mutation with HL in
Branch B (Figure 1a). This mutation did not segregate into the other
two branches. In affected subject III-4, we found two heterozygous
missense mutations c.3016G4A and c.4988A4T in the CDH23
(DFNB12) gene that resulted in amino acid substitutions p.E1006K
and p.D1663V. Sanger sequencing conﬁrmed that each parent
contributes one heterozygous allele, and only patients in Branch A
carried compound heterozygotes of CDH23 mutations (Figure 1a).
Both variants were highly conserved in vertebrates and absent from
both public and in-house databases. All rare variants that disrupt
known NSHL genes discovered from two sequenced patients are
summarized in Table 4.
Comparison of the performance of two TGE kits
To investigate the performance of the SureSelect 50Mb kit and the
CUHK-HL V1 kit, we compared the target coverage of two samples.
Of the target bases of III-13 (CUHK-HL V1 kit), 92.8% were covered
at least once, 83.3% were covered at 4= 10× and 76.5% were at
4= 20× . For III-4 (SureSelect 50Mb kit), at least 96.3% of the target
bases were covered at least once, 89.9% were covered at4= 10× and
81.0% at4= 20× (Table 5). The coverage over the exonic regions of
the 55 NSHL genes was slightly higher than the overall targets for
III-4, but similar or slightly lower than the overall targets for III-13
(Table 5).
To evaluate the enrichment efﬁciencies of the SureSelect 50Mb kit
and CUHK-HL V1 kit, we compared the proportion of on-target
bases. We found that although a larger proportion of mapped bases
captured by the CUHK-HL V1 kit were mapped onto the designed
target regions (73.2% by CUHK-HL V1 vs 60.7% by SureSelect
50Mb), the mtDNA target alone subsumed 64.7% of the on-target
bases or 47.7% of the total mapped bases (Figure 2b). It made the
mtDNA of sample III-13 extremely deeply covered (14 497.2× ).
Although the mtDNA is not targeted by the SureSelect 50Mb kit,
we can still observe a mean depth of 131.3× on mtDNA. After
excluding the mtDNA targets, the differences in the coverage at
normalized depths were also reduced (Figure 2c).
To investigate the inﬂuence of genomic features on per-target
depth, we performed multiple linear regression analysis of the
normalized per-target depth, GC content and bait density. The two
kits showed different normalized depths for low GC targets (0.3~ 0.4
GC content). Although depths of those targets in the CUHK-HL V1
kit were typically higher than the mean coverage, the depths of similar
targets in the SureSelect 50Mb kit tended to be lower than the mean
(Figure 2d). Consistently, we found GC squared was a signiﬁcant
predictor for the target depth of the SureSelect 50Mb kit but not for
the CUHK-HL V1 kit (Table 6). Target regions with low bait densities
tended to have shallower depths after accounting for the GC effect
(Figure 2e).
DISCUSSION
In the present study, we have identiﬁed three different genetic defects
in an unconventional Chinese family segregating prelingual HL with
unclear inheritance pattern. Given a high heterogeneity and its allelic
spectrum, the co-occurrence of three different genetic causes in our
pedigree is a very rare occasion but not unexpected. The heterogeneity
within a single family was reported in a number of other HL pedigrees
(summarized in Supplementary Table S3). All reported pedigrees were
resolved by using candidate gene sequencing, haplotype analysis and
sometimes aided by the audio proﬁles. In each pedigree, at least oneTa
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population-speciﬁc recurrent mutation was involved, similar to the
observation made in our pedigree.
The genetic causes in Branch B and C (SLC26A4: c.919-2A4G,
mtDNA: A1555G) represent the most common HL-causing mutations
in China,19 with an allele frequency of 0.008 in our in-house database;
whereas both of the CDH23 mutations in Branch A are private. The
mtDNA A1555G mutation was present in matrilineal relatives of
Branch C in this Chinese family, consistent with the clinical ﬁndings
that the affected subjects in Branch C (III-20, III-24 and III-29) had
historical exposures to gentamicin or streptomycin at the age of
0–2 years. The SLC26A4 gene encodes pendrin, which is a sodium-
independent chloride/iodide transporter. Mutations in this gene are
responsible for HL associated with Pendred syndrome or enlarged
vestibular aqueduct. The proband (III-11) was examined by temporal
bone computed tomography scan and revealed enlarged vestibular
aqueduct. She also underwent standard endocrinology examination
and found to have normal thyroid hormone. None of the other
patients in Branch B had self-reported goiter either, consistent with
the rarity of Pendred syndrome among Chinese patients.19 The
CDH23 gene encodes a calcium-dependent cell-adhesion protein
(cadherin) with 27 EC cadherin domains. Each EC domain contains
cadherin-speciﬁc motifs XEX, DXD, LDRE, XDX and DXNDN
required for cadherin dimerization and Ca2+ binding.20 Mutations
in CDH23 gene cause both USH1D and DFNB12. The p.E1006K
mutation was reported before,21 whereas the p.D1663V mutation was
novel. Both mutations changed the residue at the Ca2+-binding sites.
The p.E1006K mutation substituted the negatively charged glutamic
acid (E) of the XEX motif at EC10 domain to a negatively charged
lysine residue. The p.D1663V mutation substituted the second aspartic
acid (D) of the DXD motif at EC16 domain to a hydrophobic valine
residue. It is known that homozygous nonsense, frameshift, splice-site
and some missense mutations cause USH1D; and DFNB12 is caused
exclusively by the missense mutations that are presumed to retain
some residual function for retinal and vestibule but not for cochlear.
However, the functional effects of novel missense mutations cannot be
easily determined. The conserved motifs within EC domains might
facilitate the interpretation for a subset of the missense mutations.
Previously, Austo et al.22 noted that most missense mutations in the
Ca2+-binding motifs were only observed in DFNB12 patients, which
led to the suggestion that the impairment of Ca2+ binding may not
diminish cadherin’s function in retina. However, many of those
patients were compound heterozygous for two disease-causing alleles,
which confound the interpretation of the phenotypic consequence of
each allele. Later, Schultz et al.21 demonstrated that for patients
carrying compound heterozygous mutations, USH1D occurs only
when two USH1D alleles were in trans; in contrast, when there are
both DFNB12 alleles or one DFNB12 and one USH1D allele in trans,
the resulting phenotype is DFNB12. The p.E1006K mutation was
reported by Schultz et al.21 as the USH1D allele. Therefore, we can
predict that the p.D1663V mutation should be DFNB12 allele, and
masked the effect of the USH1D allele p.E1006K carried by the Branch
A patients. Further establishing the genotype–phenotype correlations
of the CDH23 missense mutations can improve the early molecular
diagnosis of USH1D patients.
We applied and compared two targeted NGS approaches in this
study. The advantage of using custom TGE kit over off-the-shelf
commercial exome kits for molecular diagnosis have been discussed
previously,11,23 including cost saving in sequencing, deeper coverage in
candidate genes, shorter turnaround time, easier data management,
etc. There was a consensus that before the clinical application of a
custom TGE kit, its performance should be extensively evaluated and
validated. In this regard, we noted that previous studies mainly
focused on evaluating the accuracy of variant calls and genotype
concordance,10,11,24 although the general problem of variant calling
and quality control was already well solved (e.g., DePristo et al.25).
Therefore, we focused in this study on the comparative evaluation of
the coverage depth, which is the major determinant of the power for
variant discovery.
In targeted resequencing projects, the sequencing is commonly
considered as completed if 80% of the target regions are covered by
4= 20× . For the application in molecular diagnosis, the coverage
requirement is higher. For the sequenced samples, we typically
observed that the achieved coverage at given depth would reach a
plateau at the increase of raw sequences. This efﬁciency trend was
known to be inﬂuenced by a number of factors including the library
complexity, kit performance and experimental conditions. Per-target
depths are known to be highly correlated among different samples
enriched and sequenced using the same platform (e.g., Plagnol
et al.26). The two TGE kits used in this study were based on the
same technology and had almost the same experimental procedures,
so the experimental differences should be controlled to the minimal.
Although different sequencing protocols were used (90 bp PE for
III-13, 100 bp PE for III-4), the results were quantitatively similar after
we redid the analyses using 90 bp PE reads (by trimming out 10 bp at
the 3´ end) of III-4. Therefore, we believe the differences observed on
the two samples mainly reﬂect the differences in the kit performances.
Table 5 The summary statistics for two sequenced affected subjects
Parameters III-13 III-4
Target enrichment kit CUHK-HL
V1
SureSelect
50Mb
Total yield of raw sequence reads (Gbp) 0.837 19.58
Percent of aligned reads 98.7% 96.3%
Percent of duplicated reads 15.8% 30.7%
Mean depth of coverage on the targeted regionsa 95.6× 110.86×
Mean depth of coverage on the mtDNA 14479.2 131.3
Percent of target bases covered at 4=1× 92.8% 96.3%
Percent of target bases covered at 4=10× 83.1% 89.9%
Percent of target bases covered at 4= 20× 76.3% 81.0%
Percent of target bases covered at 4= 30× 71.0% 72.5%
Mean depth of coverage on the NSHL gene regions 83.5× 119.9×
Percent of the NSHL gene regions covered at4=10× 85.3% 90.6%
Percent of the NSHL gene regions covered at4=20× 74.9% 83.6%
Percent of the NSHL gene regions covered at4=30× 67.3% 76.2%
Abbreviations: Gbp, giga base pair.
aWe did not include the mtDNA in calculating the average depth. If the mtDNA target of the
CUHK-HL V1 kit were included, the mean target depth for B-3 would be 213.6× ; and the
coverage proportions at 10× , 20× and 30× would be slightly increased to 83.3%, 76.5% and
71.3%, respectively.
Table 6 Evaluating the inﬂuence of the genomic features on the
per-target depth
Target enrichment kit CUHK-HL V1 SureSelect 50Mb
Dependent variables β P-value β P-value
GC percent −0.514 o2e-16 −0.245 o2e-16
Squared GC percent 0.00238 0.564 −0.218 o2e-16
Bait densitya 17.77 o2e-16 15.05 o2e-16
aBait density reﬂects the density of repeat element; target regions rich in repeat element tend to
have fewer designed baits.
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Among samples enriched by the CUHK-HL V1 kit within the same
batch, the proportion of bases mapped onto mtDNA varies from 30 to
80%, which is highly correlated with the proportion of total on-target
bases and the uniformity over all target regions (data not shown).
Although it is intuitive that higher on-target proportions for the
samples enriched by the CUHK-HL V1 kit can result from its higher
bait density, it can also be inﬂuenced by the effect of the mtDNA
target.
Our evaluation suggests rooms for improvement for our custom
TGE kit, and also illustrates several issues that need to be considered in
the kit design. First, the inclusion of the entire mtDNA as a separate
target should be treated with caution. Although the deep coverage on
mtDNA can have the beneﬁt for detecting structural variants and low-
level heteroplasmy (as demonstrated by Calvo et al.27 in diagnosing
mitochondrial disorders), it also incurred a great loss in enrichment
efﬁciency. For the genetic diagnosis of HL, which has a very limited
mutation spectrum at mtDNA,28 a dedicated target of entire mtDNA
may not be necessary. Some recent studies even demonstrated that the
mtDNA mutations could well be discovered in exome sequencing in
which mtDNA was not speciﬁcally targeted (e.g., Dinwiddie et al.29).
Second, the calibration and optimization for the TGE kit is a
complicated issue. It was shown previously that by using overlapping
baits, the NimbleGen SeqCapEZ whole-exome kit showed the highest
on-target proportion and most uniform target depths.13 Here, we
applied a similar design philosophy to our custom kit using the
Agilent’s SureSelect technology. Although we found an improvement
over the low GC targets (Figure 2d), the overall target uniformity after
excluding mtDNA did not improve over the commercial products.
Nevertheless, the observed difference is small and already offset by the
reduced sequencing amount. We also found that the use of over-
lapping baits may have a beneﬁt to reduce the reference bias for
heterozygous SNVs, because the allele balances of heterozygous SNVs
called from the samples enriched by the custom kit were closer to 0.5
and showed less variability than other whole-exome kits based on the
same technology (Supplementary Figure S2). Finally, all of the TGE
methods based on hybridization suffer from the bias caused by GC
content and repeat elements. To ﬁll in those coverage gaps, alternative
approaches like PCR-based TGE technology should be considered,30
although they suffer from other problems like variable depths across
samples, allele dropouts, etc.
Taken together, three different genetic causes of prelingual HL were
identiﬁed in this family. The apparently recessive HL in Branch C was
indeed caused by the maternally inherited mtDNA A1555G mutation
with variable penetrance (induced by ototoxic drugs). The Branch A
was diagnosed as DFNB12 caused by the compound heterozygote for
two missense mutations; and Branch B was diagnosed as DFNB4 with
enlarged vestibular aqueduct because of a homozygous splice-site
mutation. We have also evaluated two targeted NGS approaches. Our
experiences not only demonstrated the effectiveness of NGS approach
in molecular diagnosis, but also underscored the ongoing challenges in
the issues like designing the custom enrichment kit, evaluating the
pathogenicity of variants and predicting phenotype outcomes from
genotypes.
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